TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00894374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate (Test)
Description: Oral tablet, single dose, 1 x 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate (Comparator)
Description: Oral tablet, single dose, 2 x 50 mg
Study: NCT04048811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol HSK3486
Description: The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
Study: NCT02206243

Intervention type: DRUG
Intervention: Embozene Microspheres
Description: Intraarterial application
Study: NCT03767803

Intervention type: OTHER
Intervention: Non-interventional study
Description: This is an observational, non-interventional study.

Intervention type: OTHER
Intervention: Non-interventional study
Description: This is an observational, non-interventional study.
Study: NCT01695668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lotemax
Description: Ophthalmic corticosteroid. It decreases inflammation of the eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
Study: NCT05015777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emil Jaques-Dalcroze's Eurhythimcs Exercise Program
Description: Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece.
Study: NCT00959803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 3 mg solution, oral single dose.
Study: NCT03932786

Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Collection of tissue and saliva samples
Study: NCT03254667

Intervention type: BIOLOGICAL
Intervention: Brodalumab
Description: Brodalumab

Intervention type: DRUG
Intervention: Comparator Drug (non-biologic IL-17 inhibitors)
Description: Comparator subjects treated with non-biologic IL-17 inhibitors
Study: NCT03932786

Intervention type: PROCEDURE
Intervention: Biospecimen collection
Description: Collection of tissue and saliva samples

Intervention type: OTHER
Intervention: Vision assessment
Description: Undergo vision assessment
Study: NCT00959803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 10 mg solution, oral single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 25 mg solution, oral single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution, oral single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 25 mg solution, oral twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution, oral twice daily for 7 days.
Study: NCT01531192

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri 100 million CFU/day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin
Description: 50000 unit/3 times a day, both for orally and by orogastric route
Study: NCT00401674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT03529903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Our trained health coaches will use the Way To Health platform to track patient health behaviors, and will communicate with patients via both SMS text messaging (up to four messages per week) and biweekly phone calls (up to one hour). During these interactions, health coaches will connect the patient to helpful resources and to help them reflect on previous goals and to set realistic, achievable goals for the upcoming weeks.
Study: NCT02117674

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard forward-viewing colonoscopy
Description: examination of the colon with a conventional colonoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard forward-viewing colonoscopy
Description: examination of the colon with a conventional colonoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full-spectrum colonoscopy
Description: examination of the colon with full-spectrum colonoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full-spectrum colonoscopy
Description: examination of the colon with full-spectrum colonoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right colon retroflexion
Description: examination of the right colon with scope retroflexion (both with conventional and fuse scope)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right colon retroflexion
Description: examination of the right colon with scope retroflexion (both with conventional and fuse scope)
Study: NCT00750893

Intervention type: BIOLOGICAL
Intervention: Rotarix or Rotarix liquid formulation
Description: GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (oral suspension or prefilled syringe).
Study: NCT02942004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547 60 μg/kg/h
Description: Intravenous infusion of SAGE-547.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547 90 μg/kg/h
Description: Intravenous infusion of SAGE-547.
Study: NCT01250249

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine IP - Serum Institute of India
Description: 0.1 ml for adults and children aged 1 month and over 0.05 ml for infants under 1 month of age
Study: NCT00322374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Infusion, intravenous (IV): 75 mg/m\^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Infusion, intravenous (IV): 75 mg/m\^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Infusion, intravenous (IV): 75 mg/m\^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
Study: NCT00743522

Intervention type: DEVICE
Intervention: ICD/ CRT-D
Description: Cardiac device
Study: NCT03932786

Intervention type: OTHER
Intervention: Vision assessment
Description: Undergo vision assessment
Study: NCT03035071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive esophagectomy
Description: In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open esophagectomy
Description: in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
Study: NCT00570258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant: 250 mg IM Q 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: 150 mg PO QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: 250 mg IM Q 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 150 mg PO QD
Study: NCT01461993

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rLP2086 and Gardasil
Description: Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rLP2086
Description: Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
Study: NCT03093311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS based protocol
Description: Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
Study: NCT03693599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbetocin
Description: single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntometrine
Description: one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
Study: NCT03856021

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture with Bone Marrow Aspirate Concentrate
Description: Bone Marrow Aspirate Concentrate harvested and prepared from the iliac crest

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: All surgeons will use a 2 mm microfracture pick to perform the microfracture procedure. Using the 2 mm pick, surgeons will make 5 holes per 10 cm2.
Study: NCT03870087

Intervention type: DEVICE
Intervention: Robotic-assisted PCI
Description: The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
Study: NCT03932786

Intervention type: OTHER
Intervention: Questionnaire administration
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Questionnaire administration
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Quality of life assessment
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Quality of life assessment
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02522546

Intervention type: OTHER
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab
Study: NCT03041454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel systematic review format
Description: A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
Study: NCT00001259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Patches
Description: Transdermal Estradiol, 100mcg/day by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Patches
Description: Transdermal Estradiol, 100mcg/day by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Patches
Description: Transdermal Estradiol, 100mcg/day by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Patches
Description: Transdermal Estradiol, 100mcg/day by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone suppository, 200mg vaginally twice/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone suppository, 200mg vaginally twice/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone suppository, 200mg vaginally twice/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone suppository, 200mg vaginally twice/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo by skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo by skin patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo given intramuscularly monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suppository
Description: Placebo vaginal suppository
Study: NCT03932786

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00001259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suppository
Description: Placebo vaginal suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suppository
Description: Placebo vaginal suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suppository
Description: Placebo vaginal suppository
Study: NCT03806569

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MAC-cbt group treatment for adult ADHD
Description: Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Jacobson
Description: Relaxation treatment in technique of Jacobson in 8 sessions
Study: NCT01332435

Intervention type: DRUG
Intervention: 5ARI + AB
Description: 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin

Intervention type: DRUG
Intervention: 5ARI + AB
Description: 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
Study: NCT03397420

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FAM-CARE
Description: Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAM-CARE
Description: Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
Study: NCT00886821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVX-096
Description: Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
Study: NCT02398474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFP block ropivacaine
Study: NCT04021784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDS
Description: The patient is implanted with SDS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEMOST
Description: The patient is implanted with NEMOST.
Study: NCT00914628

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HSV-Tk
Description: Infusion of approximately 1±0.2 x 10\^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T-cell depleted or T-cell replete strategies
Description: Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10\^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
Study: NCT02013934

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02398474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine infiltration of the iliac crest bone
Study: NCT00758043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: 750 mg every 8 hours (q8h) for 12 weeks
Study: NCT03368924

Intervention type: OTHER
Group type: OTHER
Intervention: SCA patients (SS genotype)
Description: The clinical data relative to the patients will be collected in each of these stages (CVO, basic state).~Besides, to estimate the severity of the CVO, we shall use an index of severity of the episode ( IS2) adapted from the one who was validated by our group to stratify the severity of vasoocclusifs episodes at the drepanocytic child SS.~Main clinical parameters: taken of analgesic at home (level), temperature in the admission, SaO2 in the admission, number of painful sites, thoracic pain with or without associated cough, score EVA in the entrance, feeling of the patient of bigger gravity of the CVO with regard to its crises previous, heart rate to the admission, ... Main biological parameters: rate of leukocytes, of polynucléaires neutrophiles, of réticulocytes, Lactate déshydrogénase, of haemoglobin, C-reactive Protein ... The biological data can be studied according to their raw rate or according to their difference with their basic value (in the stable state).
Study: NCT03584685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask
Description: All participants will initially be treated without the mask. In the next appointment, half will be treated with the mask.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine wound treatment
Description: All participants will initially be treated for their wounds without the mask. In the next appointment, half will again be treated for their wounds without the mask.
Study: NCT01615861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IOL implantation
Description: Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL Implantation
Description: Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
Study: NCT03723564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringers Solution for Injection
Description: Using ultrasound guidance, a 22 gauge needle will be introduced into amniotic cavity. Warmed Lactated Ringers solution will be injected into the amniotic cavity until an AFI of 8.0 cm is achieved
Study: NCT01854333

Intervention type: OTHER
Group type: OTHER
Intervention: ADOS module 1-4 or ADI-R
Study: NCT01054911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: All patients will receive sunitinib 37.5 mg p.o. daily for up to 12 weeks to be taken orally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Following sunitinib therapy, patients will be evaluated for surgery. It is anticipated that the quality of response will allow for complete resection of residual tumor. Surgical resection, if eligible, will occur around week 14-16.
Study: NCT02271282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02271282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHRH/Ghrelin combined Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHRH/Ghrelin combined Injection
Study: NCT03450421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actamax™Adhesion Barrier
Description: Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.